Tesamorelin: GHRH Analogue in Growth-Hormone-Axis Research

Tesamorelin is a stabilised analogue of native growth-hormone-releasing hormone (GHRH(1-44)) with a hexanoyl modification on the N-terminal tyrosine that resists dipeptidyl-peptidase-mediated degradation. This modification produces a workable half-life for chronic-exposure research protocols while preserving GHRH-receptor selectivity.

Where Sermorelin corresponds to GHRH(1-29), Tesamorelin retains a longer sequence closer to the native peptide. In research designs mapping the growth-hormone axis, this makes Tesamorelin a useful reference for full-length GHRH-receptor engagement compared against Sermorelin's shorter fragment.

Published preclinical and clinical-adjacent literature has examined Tesamorelin's effect on IGF-1 signalling, visceral adiposity and lipid handling. From a laboratory-research perspective, Tesamorelin is commonly paired with Ipamorelin (a selective ghrelin-receptor agonist) in designs isolating the two arms of GH regulation.

For research-practice, Tesamorelin is supplied lyophilised and reconstitutes readily in bacteriostatic water. Reference-grade material should arrive with HPLC purity confirmation, mass-spectrometry identity and a batch COA. Reconstituted material should be aliquoted and cold-stored.

Tesamorelin remains a chemical reference standard for in-vitro and animal research. This article is intended as educational reference material only.